The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis

Br J Haematol. 2017 May;177(3):481-483. doi: 10.1111/bjh.14585. Epub 2017 Mar 14.

Authors

Ilka Decker¹, Stacey A Goodman², Sharon E Phillips³, Daniel J Lenihan⁴, Robert F Cornell²

Affiliations

¹ Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
² Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴ Department of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

PMID: 28295184
DOI: 10.1111/bjh.14585

No abstract available

Keywords: cardiac amyloidosis; haematological response; heart failure; light chain amyloidosis; six minute walk test.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amyloidosis / diagnosis*
Amyloidosis / drug therapy*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Cardiomyopathies / diagnosis*
Cardiomyopathies / drug therapy*
Combined Modality Therapy
Humans
Immunoglobulin Light Chains / metabolism*
Treatment Outcome
Walk Test*

Substances

Antineoplastic Agents
Biomarkers
Immunoglobulin Light Chains